Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: LNK01004 ointment 0.3%Drug: LNK01004 ointment 1.0%Drug: LNK01004 ointment 1.5%Drug: Vehicle BID
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Target Recruit Count
- 28
- Registration Number
- NCT06553287
- Locations
- 🇨🇳
Hospital for skin diseases, Institute of Dermatology, Chinese Academy of Medical Sciences., Nanjing, China
A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Target Recruit Count
- 354
- Registration Number
- NCT06277245
- Locations
- 🇨🇳
Dermatological Hospital of Southern Medical University, Guangzhou, China
A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Target Recruit Count
- 430
- Registration Number
- NCT06276998
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: LNK01001 Dose BDrug: LNK01001 Dose ADrug: placebo
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Target Recruit Count
- 156
- Registration Number
- NCT06099535
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Target Recruit Count
- 177
- Registration Number
- NCT06085534
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: LNK01001 Dose BDrug: LNK01001 Dose ADrug: placebo
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Target Recruit Count
- 150
- Registration Number
- NCT06085521
- Locations
- 🇨🇳
Jianzhong Zhang, Beijing, China
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
Phase 1
Withdrawn
- Conditions
- Primary MyelofibrosisAcute Myeloid LeukemiaPolycythemia VeraPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
- Interventions
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Lynk Pharmaceuticals Co., Ltd
- Registration Number
- NCT04896112
- Locations
- 🇺🇸
Revive Research Institute, Sterling Heights, Michigan, United States
© Copyright 2025. All Rights Reserved by MedPath